Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus toripalimab as first-line treatment for patients with unresectable hepatocellular carcinoma: Updated results of the ALTER-H003 trial.
Authors
Haifeng Lin
Department of Medical Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China;
Haifeng Lin , Jie Ma , Manyun Zhuo , Chengsheng Zhang , Jingru Luo , Xiaohong Zhuang , Zhiming Zeng , Lihua Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR1900028295
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 568)
DOI
10.1200/JCO.2023.41.4_suppl.568
Abstract #
568
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Preliminary results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2023 ASCO Annual Meeting
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
First Author: Arndt Vogel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
First Author: Ke-Feng Ding